drugset / Trial / NCT01517802

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

NCT01517802

Phase 3 Completed 32 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.

Timeline

Start
2012-03-28
Primary completion
2021-04-22
Completion
2021-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Background Prednisone Other / unclassified 5 mg Oral